pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,921 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1217Endpoints919BioPharma Dive354BioSpace340Fierce Biotech319onclive165raps111globenewswire health
therapy area
allOncology8285Rare Disease1943Cardiology1880Immunology1591Hematology1354Pulmonology1285Vaccines
  • Neion Bio secures $23M Series A to develop egg-based protein platform for biologics
    Neion Bio announced it closed a $23 million Series A round that was oversubscribed. The funding will be used to advance its platform that leverages chicken eggs, extracting primordial germ cells f…
    Endpoints · 3mo agoDealPositive↗ source
  • Sensorion halts development of SENS-501 for OTOF-related hearing loss after strategic review
    Sensorion announced it is ending the development of its SENS-501 candidate, which was aimed at treating OTOF-related hearing loss, following a strategic review of its pipeline. The biotech said it…
    Endpoints · 3mo agoNeutral↗ source
← prev
page 58 of 77
next →
73
fda recalls67
fda medwatch67
fda press38
1279
Psychiatry & CNS895
Ophthalmology521
Pain503
Endocrinology & Metabolism496
Infectious Disease459
  • Biopharma’s top scientists and doctors earned eight-figure pay in 2025, still far below CEO salaries
    Endpoints News released a compensation report that ranks the ten highest-paid scientists and doctors in biopharma for 2025. The list shows that several executives received eight-figure total compe…
    Endpoints · 3mo agoNeutral↗ source
  • Parabilis Medicines raises $670 million in record-setting biotech IPO on Nasdaq
    Parabilis Medicines, a Cambridge, Massachusetts drug developer, completed its initial public offering on Nasdaq, raising $670 million. The offering is described as the largest biotech IPO in indus…
    Endpoints · 3mo agoDealPositive↗ source
  • Parabilis raises $670M in record-setting Nasdaq debut to fund cancer drug development
    Parabilis completed a $670 million initial public offering on the Nasdaq, establishing the largest biotech debut in the exchange’s history. The offering drew strong investor demand even as attenti…
    Endpoints · 3mo agoDealPositive↗ source
  • Beren Therapeutics secures $300 million to fund rare disease drug launch ahead of FDA review
    Beren Therapeutics announced it has raised $300 million in new financing to support the development and launch of its rare disease therapy. The funding arrives as the company prepares for an FDA d…
    Endpoints · 3mo agoDealPositive↗ source
  • Novartis inks second molecular glue partnership with Orionis, $40M upfront
    Novartis has entered a second agreement with Orionis Biosciences focused on molecular glue technology. The deal includes an upfront payment of $40 million. The agreement also provides for mileston…
    Endpoints · 3mo agoDealPositive↗ source
  • SonoThera secures $125 million to advance ultrasound-based gene therapy for Duchenne and polycystic kidney disease
    SonoThera announced it has raised $125 million in financing to move its ultrasound-based non-viral gene therapy platform toward clinical testing. The funding will support the company’s two lead pr…
    Endpoints · 3mo agoDealPositive↗ source
  • Shattuck Labs raises $75M in public offering, selling 10.5M shares at $4 each
    Shattuck Labs announced a $75 million public offering to raise capital. The company is selling more than 10.5 million shares at $4 per share and is also issuing pre‑funded warrants to selected inv…
    Endpoints · 3mo agoDealNeutral↗ source
  • Biotech executives pocket nearly $1 billion in M&A golden parachutes, 12 receive $35M+ payouts
    An Endpoints News analysis identified a group of twelve biotech leaders who collectively earned close to $1 billion in exit compensation after selling their companies. Each of these executives sec…
    Endpoints · 3mo agoNegative↗ source
  • Ethyreal Bio secures $101M to develop treatments for Graves' disease and thyroid eye disease
    Ethyreal Bio, a newly unveiled biotech, announced it has raised $101 million in financing. The round was led by venture firms Atlas Venture and Medicxi. The capital will be used to advance therape…
    Endpoints · 3mo agoDealPositive↗ source
  • Sanofi halts Phase 3 trial of riliprubart in rare neurological disorder
    Sanofi announced it is ending the Phase 3 study of its antibody drug riliprubart aimed at treating a rare neurological disease. The decision follows a recommendation from an independent data monit…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA review
    GSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…
    Endpoints · 3mo agoDealPositive↗ source
  • Grace Science warns FDA bottleneck threatens ultra-rare gene therapy progress
    Grace Science, a biotech focused on ultra-rare diseases, has been developing a gene-therapy candidate that appeared close to regulatory approval. The company, co-founded by Nobel laureate Carolyn…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Garner Health secures $100 million funding, valuation climbs to $2.7 billion
    Garner Health announced a $100 million financing round that pushes its post‑money valuation to $2.7 billion. The capital raise was completed last month and was led by a group of venture investors.…
    Endpoints · 3mo agoDealPositive↗ source
  • Lilly proposes up to $1 billion for Alzheimer’s candidate, while Bial drops Parkinson’s program
    On June 9, 2026, Eli Lilly announced a potential licensing agreement for an Alzheimer’s disease candidate, offering an upfront payment of $10 million and the possibility of more than $1 billion bas…
    Endpoints · 3mo agoDealNeutral↗ source
  • Gilead reports positive Phase 3 HIV results while Merck's Trodelvy fails in lung cancer trial
    Gilead Sciences announced that its Phase 3 HIV trial met its primary efficacy endpoint, delivering a positive readout for the experimental therapy. In a separate study, Merck reported that its Pha…
    Endpoints · 3mo agoNeutral↗ source
  • WuXi AppTec re-added to Pentagon list of firms linked to Chinese military
    WuXi AppTec has been placed again on the Pentagon's updated list of companies that have ties to the Chinese military, according to a June 9, 2026 report. The inclusion marks renewed scrutiny of th…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Biopharma workers earned $116,648 on average in 2025, about 30% above S&P 500 peers
    The Endpoints News pay analysis found that the average biopharma employee earned $116,648 in 2025. This figure reflects compensation across the sector for that year. Compared with the broader mark…
    Endpoints · 3mo agoPositive↗ source
  • Eli Lilly's 340B claims data deadline passes, sparking potential new dispute
    Eli Lilly set a deadline for hospitals to submit 340B drug‑pricing program claims data under its new policy. The deadline has now passed, and the company has not indicated what actions it will tak…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • Biopharma CEOs see soaring compensation, new analysis to be discussed live
    Endpoints News released the first installment of its annual biopharma compensation project, breaking down the pay of the industry’s highest-earning CEOs. The company will host a Post-Hoc Live web…
    Endpoints · 3mo agoNeutral↗ source
  • K Health expands AI chatbot from symptom checker to hospital use
    K Health, a startup founded in 2016 as a symptom checking tool, is now deploying its AI chatbot within hospital environments. The shift follows a broader surge in AI driven virtual doctors that pa…
    Endpoints · 3mo agoPositive↗ source
  • Endpoints launches nominations for its 2026 Women in Biopharma project
    Endpoints announced that nominations are now open for its eighth annual Women in Biopharma initiative, which highlights contributions of women in the industry. The program, scheduled for 2026, see…
    Endpoints · 3mo agoPositive↗ source
  • Tango to launch Phase 3 trial in pancreatic cancer after promising combo results
    Tango announced plans to begin a Phase 3 trial testing a combination therapy for pancreatic cancer. The decision follows data presented at the American Society of Clinical Oncology meeting, where…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Roche to pay $700M upfront to Nurix for BTK degrader collaboration, deal up to $2.3B
    Roche announced a collaboration with Nurix Therapeutics to develop a BTK degrader for B cell malignancies. Roche will provide $700 million upfront, and the agreement could be worth up to $2.3 bill…
    Endpoints · 3mo agoDealPositive↗ source